Anifrolumab (Saphnelo) November 30, 2023
November 30, 2023 – Lupus Canada is pleased to share that Anifrolumab (Saphnelo) will be included on the Alberta Drug Benefit List effective December 1st, 2023. For details regarding this listing and renewal criteria, please visit the Alberta Drug Benefit List website.
RAMQ has also included Anifrolumab in their drug formulary update that took effect on November 8th, 2023. For more information please visit www.ramq.gouv.qc.ca/fr/a-propos/liste-medicaments.